Anke Baum
Impact in
- Oncology top 2%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Cell Biology top 2%
- Microtubule and mitosis dynamics
Papers in
- Oncology 18
- HER2/EGFR in Cancer Research 8
- Cancer Treatment and Pharmacology 3
-
- Protein Degradation and Inhibitors 6
- Co-authors
- Wolfgang J. Rettig (2 shared papers)Pilar Garin‐Chesa (7 shared papers)Günther R. Adolf (6 shared papers)Flavio Solca (10 shared papers)Frank Himmelsbach (4 shared papers)Jens Quant (4 shared papers)Martin Steegmaier (4 shared papers)Matthias Grauert (3 shared papers)
- Journals
- Journal of Pharmacology and Experimental Therapeutics (3 papers)Molecular Cancer Therapeutics (2 papers)Clinical Cancer Research (2 papers)European Journal of Cancer (2 papers)Experimental and Toxicologic Pathology (2 papers)
- Partner nations
- AustriaGermanyUnited States
In The Last Decade
Anke Baum
31 papers receiving 2.7k citations
Anke Baum's Hit Papers
Peers
Comparison fields: 5 of 86
- Oncology 1.4k
- Cell Biology 666
- Pulmonary and Respiratory Medicine 978
- Molecular Biology 1.6k
- Hematology 201
Countries citing papers authored by Anke Baum
This map shows the geographic impact of Anke Baum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke Baum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke Baum more than expected).
Fields of papers citing papers by Anke Baum
This network shows the impact of papers produced by Anke Baum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke Baum. The network helps show where Anke Baum may publish in the future.
Co-authors
The 25 scholars most cited alongside Anke Baum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Hit paper breakdown → | 2008 | 1160 |
| 2 | BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo Hit paper breakdown → | 2007 | 691 |
| 3 | 2009 | 322 | |
| 4 | 2017 | 90 | |
| 5 | 1995 | 79 | |
| 6 | 2011 | 78 | |
| 7 | 2016 | 68 | |
| 8 | 2018 | 66 | |
| 9 | 2018 | 46 | |
| 10 | 2004 | 39 | |
| 11 | 2018 | 34 | |
| 12 | 2022 | 22 | |
| 13 | 2015 | 20 | |
| 14 | 2006 | 15 | |
| 15 | 2024 | 10 | |
| 16 | 1995 | 10 | |
| 17 | 2022 | 9 | |
| 18 | Injection of the subcoracoid bursa: a cause of technical failure in shoulder arthrography. | 1989 | 9 |
| 19 | A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity. | 1999 | 7 |
| 20 | 2008 | 5 |
About Anke Baum
Anke Baum is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Hematology and Genetics, having authored 32 papers that have together received 2.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (8 papers), Protein Degradation and Inhibitors (6 papers), Multiple Myeloma Research and Treatments (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Microtubule and mitosis dynamics (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Oncology (1.4k citations), Cell Biology (666 citations), Pulmonary and Respiratory Medicine (978 citations), Molecular Biology (1.6k citations) and Hematology (201 citations). Anke Baum has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Wolfgang J. Rettig, Pilar Garin‐Chesa, Günther R. Adolf, Flavio Solca, Frank Himmelsbach, Jens Quant, Martin Steegmaier, Matthias Grauert, Matthias Hoffmann and Geoffrey I. Shapiro. Their work appears in journals such as Journal of Pharmacology and Experimental Therapeutics, Molecular Cancer Therapeutics, Clinical Cancer Research, European Journal of Cancer and Experimental and Toxicologic Pathology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.